{
  "issued_date": "2013-05-02", 
  "original_url": "http://www.mhra.gov.uk/Publications/Safetywarnings/DrugAlerts/CON270708", 
  "doc_details": {
    "Type": "Drug Alert", 
    "Series No": "EL (13)A/14", 
    "Audience": "Healthcare professionals", 
    "Published": "2 May 2013", 
    "Format": "Electronic only", 
    "Size": "A4", 
    "Pages": "2", 
    "Price": "Free", 
    "ISBN/ISSN": "", 
    "Author": "", 
    "Copyright": "Crown"
  }, 
  "_assets": [
    {
      "content_type": "application/pdf", 
      "title": " Class 4 Drug Alert (Caution in Use): Ativan Injection 4mg/ml - Pfizer Limited - EL (13)A/14 (215Kb)", 
      "assetid": 0, 
      "original_url": "http://www.mhra.gov.uk/home/groups/is-md/documents/drugalert/con270710.pdf", 
      "filename": "downloads/f271bb06b5b33949fcddd11d05cd39249e14bfc3/con270710.pdf", 
      "original_filename": "con270710.pdf"
    }
  ], 
  "body": "## DRUG ALERT\n\nCLASS 4 MEDICINES DEFECT INFORMATION\n\nCaution in Use\n\n  \n\n\nDistribute to Pharmacy Level  \n  \n02 May 2013  |   |  EL (13)A/14  |   |  Our ref:\u00a0 MDR 63-04/13   | \n\n* * *\n\nDear Healthcare Professional,\n\nPfizer Limited\n\nAtivan Injection 4mg/ml\n\n(Lorazepam)\n\nPL 00057/1279\n\n  \n  \n  \nBatch number  |   |  Expiry date  |   |  Pack size  |   |  First distributed  |   \n4004  |   |  July 2013  |   |  10 x 1ml  |   |  8 October 2012  |   \n4005  |   |  July 2013  |   |  10 x 1ml  |   |  18 December 2012  |   \n4007  |   |  September 2013  |   |  10 x 1ml  |   |  5 February 2013  |   \n4009  |   |  December 2013  |   |  10 x 1ml  |   |  9 April 2013  | \n\nPfizer Limited has informed us that during routine testing and subsequent investigation of some unreleased batches of Ativan Injection which had been subjected to automated visible inspection during manufacture, a very small number of ampoules containing glass particles were identified. The incidence rate, at <0.01%, is very low. The batches listed in the above table have already been released to the market and whilst there is no evidence to suggest that they are affected by this issue (Pfizer has received no customer complaints or adverse reaction reports related to this matter), it cannot be ruled out.\u00a0\n\nSince Pfizer is the only UK Marketing Authorisation Holder for this product and there is no alternative stock available, these batches are not at present being recalled. As a precaution in the meantime, however, the following procedures should be followed prior to administration:  \n  \n  * Visually inspect the contents of each ampoule carefully for particulate matter. Reject the ampoule if any particulate matter is discovered. Please report any findings to Pfizer Medical Information on 01304 616161  \n  * Follow all recommended steps for product dilution in accordance with the product information.  \n  * Pre-filter the product prior to administration by using 5 micron filter needles or filter straws when drawing it into the syringe.  \n  * Remove the filter needle or filter straw from the syringe and replace with a new sterile needle for administration.  \n  \nFor medical information enquiries, please contact Pfizer Medical Information on 01304 616161\n\nFor any stock related enquiries, please contact Pfizer\u2019s Customer Contact Centre on 0845 608 8866 and select option 2.\n\nRecipients of this Drug Alert should bring it to the attention of relevant contacts by copy of this letter. Local area teams are asked to forward this to relevant clinics, general practitioners and community pharmacists for information.\n\nYours faithfully\n\nAlison Bunce  \nPharmaceutical Assessor  \nDefective Medicines Report Centre  \n151 Buckingham Palace Road  \nLondon  \nSW1W 9SZ  \nTelephone +44 (0)20 3080 6574\n\nMHRA Distribution (further recipients by cascade):  None \n\n### Download documents:  \n  \n  * [ASSET_TAG](#ASSET0)\n", 
  "raw_html": "<div class=\"inner\">          \r\n\t\t\t\t<a name=\"main\"></a>\r\n\t\t\t\t\r\n\t\t\t\t<div class=\"title\">\r\n\t\t\t\t\t<h2>DRUG ALERT</h2>\r\n\t\t\t\t\t<!--SS_BEGIN_ELEMENT(region1_element14)-->\r\n\t\t\t\t\t<p>CLASS 4 MEDICINES DEFECT INFORMATION</p>\r\n\t\t\t\t\t<!--SS_END_ELEMENT(region1_element14)-->\r\n\t\t\t\t</div>\r\n\t\t\t\t\r\n\t\t\t\t<div class=\"drugalertdetails\">\r\n\t\t\t\t\t<!--SS_BEGIN_ELEMENT(region1_element15)-->\r\n\t\t\t\t\t<p>Caution in Use</p>\r\n\t\t\t\t\t<!--SS_END_ELEMENT(region1_element15)-->\r\n\t\t\t\t\t<br>\r\n\t\t\t\t\t<!--SS_BEGIN_ELEMENT(region1_element16)-->\r\n\t\t\t\t\t<p>Distribute to Pharmacy Level</p>\r\n\t\t\t\t\t<!--SS_END_ELEMENT(region1_element16)-->\r\n\t\t\t\r\n\t\t\t\t\t<table id=\"dateref\">\r\n\t\t\t\t\t\t<tr>\r\n\t\t\t\t\t\t\t<td align=\"left\">\r\n\t\t\t\t\t\t\t\r\n\r\n\t\t\t\t\t\t\t02 May 2013\r\n\t\t\t\t\t\t\t</td>\r\n\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t<td>\r\n\t\t\t\t\t\t\tEL (13)A/14\r\n\t\t\t\t\t\t\t</td>\r\n\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t<td align=\"right\">\r\n\t\t\t\t\t\t\t\tOur ref:&#160;\r\n\t\t\t\t\t\t\t\t<!--SS_BEGIN_ELEMENT(region1_element17)-->\r\n\t\t\t\t\t\t\t\t MDR 63-04/13 \r\n\t\t\t\t\t\t\t\t<!--SS_END_ELEMENT(region1_element17)-->\r\n\t\t\t\t\t\t\t</td>\r\n\t\t\t\t\t\t</tr>\r\n\t\t\t\t\t</table>\r\n\t\t\t\t</div>\r\n\t\t\t\t<hr>\t\t\t\t\r\n          \t\t<!--SS_BEGIN_ELEMENT(region1_element12)-->\r\n          \t\t<!--SS_END_ELEMENT(region1_element12)--> \r\n          \t\t\r\n          \t\t \r\n          \t\t\r\n          \t\t<p>Dear Healthcare Professional,</p>\r\n\r\n\t\t\t\t<div class=\"druginfo\">\r\n\t\t\t\t\t<div class=\"left\">\r\n\t\t\t\t\t\t\r\n\t\t\t\t\t\t\r\n\t\t\t\t\t\t<p>\r\n\t\t\t\t\t\t\t<span>Pfizer Limited</span>\r\n\t\t\t\t\t\t</p>\r\n\t\t\t\t\t\t\t\t\t\t\r\n          \t\t          \t\t\t\t\r\n\t\t\t\t\t\t\r\n\t\t\t\t\t\t\r\n\t\t\t\t\t\t<p>\r\n\t\t\t\t\t\t\t<span>Ativan Injection 4mg/ml</span>\r\n\t\t\t\t\t\t</p>\r\n\t\t\t\t\t\t\r\n\t\t\t\t\t\t\r\n\t\t\t\t\t\t\r\n\t\t\t\t\t\t\r\n\t\t\t\t\t\t<p>\r\n\t\t\t\t\t\t\t<span>(Lorazepam)</span>\r\n\t\t\t\t\t\t</p>\r\n\t\t\t\t\t\t\r\n\t\t\t\t\t</div>\r\n\t\t\t\t\t\r\n\t\t\t\t\t<div class=\"right\">\r\n\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t<span>PL 00057/1279</span>\r\n\t\t\t\t\t\t\r\n\t\t\t\t\t</div>\t\r\n\t\t\t\t</div>\t\t\t\t\r\n          \t\t\r\n\t\t\t\t<!-- SS_BEGIN_SNIPPET(fragment8,navigation_controls)-->\r\n\t\t\t\t<!-- only show the publication navigation controls if there is more than one page to the publication -->\r\n\t\t\t\r\n\t\t\t\t<!-- SS_END_SNIPPET(fragment8,navigation_controls)-->\r\n \t\t\r\n\t\t\t\t<!-- SS_BEGIN_SNIPPET(region1_element2,paged_publication)-->\r\n        \t\t<!-- <br>SS_DATAFILE: CON270708 -->\r\n\r\n<!-- call include to dynamically insert alt attributes into image tags within a wysiwyg element -->\r\n<!-- get a reference to the wysiwyg content -->\r\n<!-- parse hyperlinked images -->\r\n<!-- parse word documents -->\r\n<!-- parse powerpoint documents -->\r\n<!-- parse excel documents -->\r\n<!-- parse pdf documents -->\r\n<!-- parse links to the site -->\r\n<!-- remove all hardlinks to cms -->\r\n<!-- replace /stellent/ with current webroot -->\r\n<!-- parse hyperlinked images -->\r\n<!-- parse word documents -->\r\n<!-- parse powerpoint documents -->\r\n<!-- parse excel documents -->\r\n<!-- parse pdf documents -->\r\n<!-- parse links to the site -->\r\n<!-- remove all hardlinks to cms -->\r\n<!-- replace /stellent/ with current webroot -->\r\n<p><br>\n</p><table border=\"1\" cellspacing=\"0\" cellpadding=\"0\">\n<tr>\n<td width=\"156\" valign=\"top\">\n <span>Batch number</span>\n</td>\n<td width=\"164\" valign=\"top\">\n <span>Expiry date</span>\n</td>\n<td width=\"164\" valign=\"top\">\n <span>Pack size</span>\n</td>\n<td width=\"174\" valign=\"top\">\n <span>First distributed</span>\n</td>\n</tr>\n\n<tr>\n<td width=\"156\" valign=\"top\">\n 4004 \n</td>\n<td width=\"164\" valign=\"top\">\n July 2013 \n</td>\n<td width=\"164\" valign=\"top\">\n 10 x 1ml \n</td>\n<td width=\"174\" valign=\"top\">\n 8 October 2012 \n</td>\n</tr>\n\n<tr>\n<td width=\"156\" valign=\"top\">\n 4005 \n</td>\n<td width=\"164\" valign=\"top\">\n July 2013 \n</td>\n<td width=\"164\" valign=\"top\">\n 10 x 1ml \n</td>\n<td width=\"174\" valign=\"top\">\n 18 December 2012 \n</td>\n</tr>\n\n<tr>\n<td width=\"156\" valign=\"top\">\n 4007 \n</td>\n<td width=\"164\" valign=\"top\">\n September 2013 \n</td>\n<td width=\"164\" valign=\"top\">\n 10 x 1ml \n</td>\n<td width=\"174\" valign=\"top\">\n 5 February 2013 \n</td>\n</tr>\n\n<tr>\n<td width=\"156\" valign=\"top\">\n 4009 \n</td>\n<td width=\"164\" valign=\"top\">\n December 2013 \n</td>\n<td width=\"164\" valign=\"top\">\n 10 x 1ml \n</td>\n<td width=\"174\" valign=\"top\">\n 9 April 2013 \n</td>\n</tr>\n</table>\n\n<p>Pfizer Limited has informed us that during routine testing and subsequent investigation of some unreleased batches of Ativan Injection which had been subjected to automated visible inspection during manufacture, a very small number of ampoules containing glass particles were identified. The incidence rate, at &lt;0.01%, is very low. The batches listed in the above table have already been released to the market and whilst there is no evidence to suggest that they are affected by this issue (Pfizer has received no customer complaints or adverse reaction reports related to this matter), it cannot be ruled out.&#160;</p>\n\n<p>Since Pfizer is the only UK Marketing Authorisation Holder for this product and there is no alternative stock available, these batches are not at present being recalled. As a precaution in the meantime, however, the following procedures should be followed prior to administration:</p>\n\n<ul>\n<li>Visually inspect the contents of each ampoule carefully for particulate matter. Reject the ampoule if any particulate matter is discovered. Please report any findings to Pfizer Medical Information on 01304 616161</li>\n</ul>\n\n<ul>\n<li>Follow all recommended steps for product dilution in accordance with the product information.</li>\n</ul>\n\n<ul>\n<li>Pre-filter the product prior to administration by using 5 micron filter needles or filter straws when drawing it into the syringe.</li>\n</ul>\n\n<ul>\n<li>Remove the filter needle or filter straw from the syringe and replace with a new sterile needle for administration.</li>\n</ul>\n\n<p>For medical information enquiries, please contact Pfizer Medical Information on 01304 616161</p>\n\n<p>For any stock related enquiries, please contact Pfizer&#8217;s Customer Contact Centre on 0845 608 8866 and select option 2.</p>\n\n<p>Recipients of this Drug Alert should bring it to the attention of relevant contacts by copy of this letter. Local area teams are asked to forward this to relevant clinics, general practitioners and community pharmacists for information.</p>\n\n<p align=\"left\">Yours faithfully</p>\n\n<p align=\"left\">Alison Bunce<br>\nPharmaceutical Assessor<br>\n<span>Defective Medicines Report Centre<br>\n151 Buckingham Palace Road<br>\nLondon<br>\nSW1W 9SZ<br>\nTelephone +44 (0)20 3080 6574</span></p>\r\n\r\n\t\t\t\r\n        \t\t<!-- SS_END_SNIPPET(region1_element2,paged_publication)-->\r\n        \t\t\r\n        \t\tMHRA Distribution (further recipients by cascade):\r\n        \t\t\r\n        \t\t <!--SS_BEGIN_ELEMENT(region1_element18)-->\r\n        \t\tNone\r\n        \t\t<!--SS_END_ELEMENT(region1_element18)-->\r\n \t\t\r\n\t\t\t\t<!-- SS_BEGIN_SNIPPET(region1_element3,static_pdf_list)-->\r\n        \t\t<!-- the xmlListTag variable is used by the searchDocsByContentIdList include to map the name of the XML node which contains the content id -->\r\n<!--perform the search -->\r\n\t\r\n\t<!-- <br>root: Content/AssociatedContent -->\r\n\t<!-- <br>ssFragmentInstanceId: region1_element3\t -->\r\n\t<!-- <br>SS_DATAFILE: CON270708 -->\r\n\t<!-- <br>xmlListTag: ContentId\t -->\r\n\t<!-- <br>XPATH: CON270708/Content/AssociatedContent/ContentId\t -->\r\n\r\n\t<!-- xmlListTag variable should be the name of the xml node which contains a contentid.  there should be a lis of these in the XML -->\r\n\t<!-- <br>strNumRecords: 1 -->\r\n\t<!-- <br>nNumRecords: 1 -->\r\n\r\n\t\t\t<!-- using the content ID above, get the docment from conetent server-->\r\n\r\n\t\t\t\r\n\r\n\t\t<!--  dDocName <matches>`CON270710` -->\r\n\t\t\r\n<div id=\"downloadArea\">\r\n\t<h3>Download documents:</h3>\r\n\t<ul>\r\n\t\t<!-- the SearchResults will have been initialised by the call to searchDocsByContentIdList above-->\r\n\t\t\t\r\n\t\t\t\t<li>\r\n\r\n\t\t\t\t\t\t<a href=\"#ASSET0\">ASSET_TAG</a>\r\n\t\t\t\t</li>\r\n\t</ul>\r\n\t<div class=\"clearing\"><!--  --></div>\r\n\t<!--<p><a class=\"doubleArrow\" target=\"new\" href=\"http://www.adobe.com/products/acrobat/readstep2.html\">Download Acrobat Reader for free</a></p>\r\n\t<p><a class=\"doubleArrow\" target=\"new\" href=\"http://www.adobe.com/products/acrobat/access_onlinetools.html\">Adobe text conversion tools</a></p>-->\r\n</div>\r\n\t\t\t\r\n        \t\t<!-- SS_END_SNIPPET(region1_element3,static_pdf_list)-->\r\n \t\t\r\n\t\t\t\t<!-- SS_BEGIN_CLOSEREGIONMARKER(region1)-->\r\n        \t\t\r\n        \t\t<!-- SS_END_CLOSEREGIONMARKER(region1)-->\r\n\t\t\t</div>\r\n\t\t", 
  "title": "Class 4 Drug Alert (Caution in Use): Ativan Injection 4mg/ml - Pfizer Limited - EL (13)A/14", 
  "alert_type": [
    "drugs"
  ], 
  "medical_specialism": []
}